

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



信銘生命科技集團有限公司
Aceso Life Science Group Limited
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 00474)

HAO TIAN INTERNATIONAL
CONSTRUCTION INVESTMENT GROUP LIMITED
昊天國際建設投資集團有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1341)

JOINT ANNOUNCEMENT

**COMPLETION OF
MAJOR TRANSACTION**

**DISPOSAL OF SHAREHOLDING
INTEREST IN A SUBSIDIARY BY ALS**

VOLUNTARY ANNOUNCEMENT

**COMPLETION OF
INTRODUCTION OF STRATEGIC
INVESTOR BY THE
CONTROLLING SHAREHOLDER
TO HTICI**

Financial Adviser to Aceso Life Science Group Limited



References are made to the joint announcement of ALS and HTICI dated 27 July 2023 (the “**Announcement**”) and the circular of ALS dated 17 August 2023 in relation to the Disposal. Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the Announcement.

COMPLETION OF THE AGREEMENT

The ALS Board is pleased to announce that all conditions precedent under the Agreement have been fulfilled and Completion took place on 17 October 2023.

The Purchaser, being a wholly-owned subsidiary of Yitai Coal, has become a strategic investor of HTICI and holds approximately 18.37% of the entire issued share capital of HTICI.

The shareholding structure of HTICI immediately before and after Completion are as follows:

	Immediately before Completion		Immediately after Completion	
	No. of shares in HTICI	Approximate %	No. of shares in HTICI	Approximate %
ALS (Note 1)	3,611,701,259	47.40	2,211,613,259	29.03
Li Shao Yu (Note 2)	14,104,000	0.19	14,104,000	0.19
Lin Yuan (Note 3)	891,264,000	11.70	891,264,000	11.70
Fok Chi Tak (Note 4)	60,975,610	0.80	60,975,610	0.80
Xu Lin (Note 5)	2,764,228	0.04	2,764,228	0.04
Purchaser	–	–	1,400,088,000	18.37
Other public shareholders	<u>3,038,961,624</u>	<u>39.87</u>	<u>3,038,961,624</u>	<u>39.87</u>
Total	<u><u>7,619,770,721</u></u>	<u><u>100.00</u></u>	<u><u>7,619,770,721</u></u>	<u><u>100.00</u></u>

Notes:

1. Among 3,611,701,259 shares in HTICI, (i) 2,000,000,000 shares were held through the Vendor, (ii) 1,540,272,688 shares were held through Hao Tian Management (Hong Kong) Limited and (iii) 71,428,571 shares were held through Hao Tian Finance Company Limited.
2. The 14,104,000 shares in HTICI were held by Ms. Li Shao Yu as beneficial owner. Ms. Li Shao Yu is the controlling shareholder of ALS and is therefore also deemed to be interested in those shares in HTICI held by ALS.
3. Pursuant to the disclosure form dated 11 January 2023 (being the latest disclosure form filed up to the date of this announcement) as published on the website of the Stock Exchange, Ms. Lin Yuan (“**Ms. Lin**”) was beneficially interested in the total of 891,264,000 shares in HTICI, among which, 391,264,000 shares are held by Ms. Lin as beneficial owner, and 500,000,000 shares are held by Soaring Wealth Ventures Limited, a company wholly-owned by Ms. Lin.

4. Mr. Fok Chi Tak, being an executive Director and an executive director and the chief executive officer of HTICI, is interested in 60,975,610 shares of HTICI as at the date of this announcement.
5. Mr. Xu Lin, being a non-executive director of HTICI, is interested in 2,764,228 shares of HTICI as at the date of this announcement.

By Order of the Board
Aceso Life Science Group Limited
Fok Chi Tak
Executive Director

By Order of the Board
**Hao Tian International Construction
Investment Group Limited**
Fok Chi Tak
Executive Director

Hong Kong, 17 October 2023

As at the date of this announcement, the ALS Board comprises three executive Directors, namely Mr. Xu Hai Ying, Dr. Zhiliang Ou, JP (Australia) and Mr. Fok Chi Tak; and three independent non-executive Directors, namely Mr. Chan Ming Sun Jonathan, Mr. Lam Kwan Sing and Mr. Mak Yiu Tong.

As at the date of this announcement, the HTICI Board comprises three executive directors, namely Mr. Fok Chi Tak, Mr. Tang Yiu Chi James and Dr. Zhiliang Ou, J.P. (Australia); one non-executive director, namely Mr. Xu Lin; and four independent non-executive directors, namely Mr. Mak Yiu Tong, Mr. Li Chi Keung Eliot, Mr. Shek Lai Him Abraham and Mr. Chan Ming Sun Jonathan.